We suggest that HML-2 expression may have diagnostic potential, could serve as a marker for treatment efficacy, and may be an excellent novel therapeutic target in CNS embryonal tumors, as is the case for AT/RT. This evidence concerns the gene CLEC10A and embryonal neoplasm.